To: fingolfen who wrote (164699 ) 4/29/2002 4:13:09 PM From: Tony Viola Read Replies (1) | Respond to of 186894 Remember what I and others said in the past about AMD's transistors already being essentially 0.13 micron on the 0.18 micron bulk process. Yup, good call, and one of the reasons I stay with this board. Besides being fun, most of the time, it is informative like no other venue I know. Here's some good, solid development work going on with Itanium and a couple other companies. Oh, one of them is Microsoft. ============================================================================= PolyMedica Selected for Joint Development Program With Microsoft, Unisys and Intel Liberty Unit is Only Healthcare Company in Project WOBURN, Mass.--(BUSINESS WIRE)--April 29, 2002--PolyMedica Corporation (NNM:PLMD) today announced that its Liberty Medical Supply, Inc. subsidiary has been chosen to participate in the SQL Server 2000 64-bit Joint Development Program (JDP) with Microsoft Corporation, Unisys Corporation and Intel Corporation. "This alliance offers an unprecedented opportunity to continue our leadership in the technology sector of the medical call center arena," said Chairman and CEO, Steven Lee. "With this new relationship, Liberty will further enhance its ability to serve its customers with the best available technology and most efficient automated systems." "Microsoft has selected Liberty Medical because of Liberty's extensive use of sophisticated data mining, modeling methodologies and the high volume of online transactions. These types of application profiles are enhanced by our upcoming release of Microsoft SQL Server 2000 64-bit," said Stan Sorensen, director of SQL Server at Microsoft. "Liberty is pleased to be associated with three of the premier companies in information processing and is enthusiastic about evolving to the next level of enterprise-class solutions," said George Narr, PolyMedica's Chief Information Officer. "We believe that these two technologies could be a significant step toward mainframe-style computing on Windows- and Intel-based technology." Liberty's enterprise applications will be tested on the high-performance Enterprise Server Unisys ES7000 with 64-bit hardware architectures based on Intel Itanium processors. The ES7000 supports 64 GB of memory and up to 32 processors. Microsoft's Windows Server and SQL Server 64 bit will take advantage of all the enhanced resources available on the ES7000. By capitalizing on these emerging technologies, Liberty will benefit greatly from a platform that is architecturally designed to scale to meet their most demanding levels of reliability, manageability, scalability and enterprise computing solutions. "Liberty is focused on the Microsoft platform through its close involvement with Microsoft on this Joint Development Program," Mr. Narr concluded. About PolyMedica (www.polymedica.com) PolyMedica is a rapidly growing national medical products and services company. The Company is best known through its Liberty brand name and innovative direct-to-consumer television advertising to seniors with diabetes and respiratory disease. Liberty Medical has the nation's largest direct-mail customer base of Medicare-eligible seniors with diabetes. Building on its technology-based operating platform and compliance management focus, PolyMedica continues to expand its product offerings and services in these chronic disease categories. In addition, the Company's AZO line of products addresses female urinary tract discomfort, where it is the market leader. PolyMedica is included in the Russell 2000 and S&P Small Cap 600 indices. This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such risks and uncertainties include the usual uncertainties about the outcome of any technology development program, including the possibility that the results achieved may be less beneficial to the Company than initially anticipated. Such risks also include, but are not limited to, changes affecting the Company's business and prospects, including developments in government inquiries and investigations, continued compliance with government regulations, unanticipated regulatory changes, changes in Medicare reimbursement, fluctuations in customer demand, management of rapid growth, intensity of competition from other healthcare product vendors, timing and acceptance of new product introductions, general economic conditions and regulatory changes, as well as other especially relevant risks detailed in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended March 31, 2001 and Quarterly Reports on Form 10-Q for the periods ended June 30, 2001 September 30, 2001, and December 31, 2001and the information set forth herein should be read in light of such risks. The Company assumes no obligation to update the information contained in this press release. biz.yahoo.com